Abstract
Objective:
To evaluate the safety and efficacy of tirofiban in high risk patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) after percutaneous coronary intervention (PCI).
Methods:
A total of 240 patients were randomized to either a tirofiban group or a control group.
Results:
Compared with the control group, the platelet aggregation rate in the tirofiban group was lower (P < 0.01); the plasma levels of CK-MB and troponin I, cardiac form (cTnI) were lower (P < 0.05); ECG improved significantly (P < 0.05); the incidence of major adverse cardiac events (MACE) was lower (P < 0.05); and there was no difference in bleeding complications between the 2 groups (P = 0.1).
Conclusions:
The administration of tirofiban in high risk patients with NSTE-ACS after PCI is safe and effective.
Copyright 2009 Wiley Periodicals, Inc.
Publication types
-
Randomized Controlled Trial
MeSH terms
-
Acute Coronary Syndrome / drug therapy
-
Acute Coronary Syndrome / mortality
-
Acute Coronary Syndrome / therapy*
-
Aged
-
Angioplasty, Balloon, Coronary / adverse effects*
-
Angioplasty, Balloon, Coronary / mortality
-
Biomarkers / blood
-
Creatine Kinase, MB Form / blood
-
Double-Blind Method
-
Electrocardiography
-
Female
-
Heart Diseases / blood
-
Heart Diseases / etiology
-
Heart Diseases / mortality
-
Heart Diseases / prevention & control*
-
Hemorrhage / chemically induced
-
Humans
-
Male
-
Middle Aged
-
Platelet Aggregation / drug effects
-
Platelet Aggregation Inhibitors / adverse effects
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Prospective Studies
-
Risk Assessment
-
Thrombocytopenia / chemically induced
-
Time Factors
-
Tirofiban
-
Treatment Outcome
-
Troponin I / blood
-
Tyrosine / adverse effects
-
Tyrosine / analogs & derivatives*
-
Tyrosine / therapeutic use
Substances
-
Biomarkers
-
Platelet Aggregation Inhibitors
-
Troponin I
-
Tyrosine
-
Creatine Kinase, MB Form
-
Tirofiban